'Not Happy' with Progress of Calando Phase I Solid Tumor Rx, Arrowhead Adding Third Clinical Site

Arrowhead's CEO said that the firm wants to accelerate enrollment in the study in order to meet its goal of completing the trial by year end.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.